Company: NIVFW
Filing Date: 2025-10-31
Form Type: 424B3
Source: 0001213900-25-104469
Chunk: 139

Company: NewGenIvf Group Ltd
Filing Date: 2025-10-31
Form: 424B3
Chunk 139
---
 those services.                                        |

The Company enters into verbal
agreements with its customers that outline the rights, responsibilities, and obligations of each party. The agreements also identify
the scope of services, service fees, and payment terms. Agreements are acknowledged and consent forms are signed by the customers prior
to each promised service or bundle of services that are inter dependent. All the contracts have commercial substance, and it is probable
that the Company will collect considerations from its customers for service component as settlement is predominantly required prior to
performance of the promised service.

The Company derives its revenues
from two sources: (1) revenue from IVF treatment, and (2) revenue from surrogacy and ancillary caring services.

Revenue from IVF treatment

In vitro fertilization (“IVF”)
treatment is an assisted reproductive technique where eggs and sperm are collected and fertilized in laboratory to become embryo. Fertilized
embryo is then implanted to the customer or a surrogate mother. IVF treatment involves the performance of a series of medical treatment
as well as procedures and brings benefits to clients as the service of bundles service is completed. Revenue from IVF treatment is recognized
at a point in time when different treatment and/or procedure or bundles thereof, are completed in clinic. The full completion of the
various procedures and treatments are evidenced by treatment cards and reports included within the patient files indicating successful
completion of the service.

<div align='center'>78</div>

Revenue from surrogacy and ancillary caring services

The Company provides surrogacy
and ancillary caring services solely in Kyrgyzstan. Embryo from blood parents is implanted to surrogate mother contracted by the Company
or its agents. During pregnancy period, the Company provides ancillary caring services including regular body check and provision of
vitamins, supplements and medicines to surrogate mothers. The key performance obligation is identified as a single performance obligation
where a baby is born, therefore revenue from surrogacy and ancillary caring services is recognized at a point in time when surrogate
mother gives birth. The Company collects approximately 40% of contract sum upfront, and remaining contract sum is collected in installments
across pregnancy period of surrogate mother. The amount of revenue recognized from contract liabilities to the Company’s result
of operations can be found in Note 8 below.

Revenue from egg freezing and storage facility

The Company provides access
to the facility to its customers. Upon request for the service, which is agreed verbally and followed by signed consent form from the